Lupus kidney drug showdown: which one wins?
NCT ID NCT07031674
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked back at medical records of 56 adults with lupus nephritis to compare two drugs: telitacicept and belimumab. The goal was to see which drug better protects kidney function and causes fewer side effects. Participants had already been on one of the drugs for at least 12 weeks. The study did not give any new treatments—it just analyzed existing data.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BELIMUMAB are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Qianfoshan Hospital
Jinan, Shandong, 250000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smartphone app bridge the lupus care gap for women of color?
- Can a single drug calm lupus kidney disease without a cocktail of meds?
- Cancer drug shows promise for lupus kidney disease
- Engineered immune cells take aim at autoimmune kidney diseases
- New drug combo aims to tame lupus kidney disease in kids
- Engineered immune cells take aim at childhood autoimmune diseases